학술논문
Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
Document Type
Article
Author
Lai, Francisco Tsz Tsun; Leung, Miriam Tim Yin; Chan, Edward Wai Wa; Huang, Lei; Lau, Lauren Ka Wun; Peng, Kuan; Leung, Janice Ching Nam; Fan, Min; Chen, Kailin; Lum, Dawn Hei; Li, Xue; Chui, Celine Sze Ling; Wan, Eric Yuk Fai; Wong, Carlos King Ho; Lam, Edwin Fung Shing; Cheung, Terence Yung Yan; Cowling, Benjamin John; Wong, Ian Chi Kei; Chan, Esther Wai Yin
Source
Subject
*COVID-19 vaccines
*LONGITUDINAL method
*COHORT analysis
*ODDS ratio
*ALLERGIES
*
*
*
*
Language
ISSN
0264-410X
Abstract
CoronaVac (Sinovac) Covid-19 vaccine has recently been approved for emergency use by the World Health Organization. However, data on its reactogenicity in real-world settings is scant. This study aimed to compare self-reported post-vaccination adverse reactions between CoronaVac and Comirnaty (Pfizer-BioNTech). We adopted a prospective cohort study design using online surveys from the day of first-dose vaccination with intensive follow-up through two weeks after the second dose (11 time points). The primary outcome was adverse reactions (any versus none) and secondary outcomes were the sub-categories of adverse reactions (local, systemic, and severe allergic reactions). Potential effect modification across multimorbidity status, older age, and sex was examined. In total, 2,098 participants who were scheduled to complete the 14th-day survey were included, with 46.2% receiving Comirnaty. Retention rate two weeks after the second dose was 81.0% for the CoronaVac group and 83.6% for the Comirnaty group. Throughout the follow-up period, 801 (82.7%) of those receiving Comirnaty and 543 (48.1%) of those receiving CoronaVac reported adverse reactions. Adjusted analysis suggested that compared with Comirnaty, CoronaVac was associated with 83%-reduced odds of any adverse reactions [adjusted odds ratio (AOR) = 0.17, 95% confidence interval (CI) 0.15–0.20], 92%-reduced odds of local adverse reactions (AOR = 0.08, 95% CI 0.06–0.09), and 76%-reduced odds of systemic adverse reactions (AOR = 0.24, 95% CI 0.16–0.28). No significant effect modification was identified. This post-marketing study comparing the reactogenicity of Covid-19 vaccines suggests a lower risk of self-reported adverse reactions following vaccination with CoronaVac compared with Comirnaty. [ABSTRACT FROM AUTHOR]